and colitis patients across >100 participating hospitals with a long-standing goal of fostering IBD Research to expedite clinical translation. For each patient recruited, clinical and self-reported phenotype data are collected, alongside plasma, serum and DNA samples for genetic analyses. The resulting data-rich panel is open to any investigators wishing to access data/samples or recall genotype-selected participants to donate further samples or trial novel therapies.

**Methods** Building the IBD BioResource panel: Patients’ clinical data are collected at recruitment by the IBD team through a clinical data sheet based on the Montreal classification while health and lifestyle information are obtained via a patient questionnaire. All include demographics, smoking habits, general and IBD specific health questions, family history of IBD and non-IBD conditions, medication, treatment, surgery history and co-morbidities. The IBD BioResource panel also holds Whole Genome/Exome sequencing and GWAS data derived from its detailed biological samplings.

Accessing the IBD BioResource panel: The built-in panel of patients and their data is open to any investigators from science or industry. Following feasibility checks, submitted research applications are reviewed by the NIHR BioResource Scientific Advisory Board (SAB) based on scientific merits and projected benefit to patients. Upon study approval, patients meeting inclusion criteria are contacted by the NIHR BioResource team with a letter of invitation and a patient information leaflet. For volunteers willing to participate, appropriate arrangements are then made to gather information, collect fresh biological samples or engage patients in intervention studies.

**Results**

**P135 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHN’S: THE SCOTTISH USTEKINUMAB COHORT**

1. **Introduction** Ustekinumab (UST) is an anti-IL12/23 biologic licensed for the treatment of moderate to severe Crohn’s disease (CD). The aims of this study were to establish the long-term real-world effectiveness and safety of UST for the treatment of CD in a large UK cohort.

2. **Methods** This was a multicentre retrospective cohort study including 8 NHS health-boards in Scotland. Patients treated with UST between Nov 2015 and Jun 2019 were identified. Inclusion criteria included: a diagnosis of CD; active symptoms attributed to CD with objective evidence of mucosal inflammation (CRP >5 mg/L or faecal calprotectin ≥250 µg/g or inflammation on endoscopy/MRI); completion of standard induction; week 8 review ± further follow up. Clinical assessments were performed based on physician global assessment (response was defined as ≥50% reduction in CD-related symptoms and remission defined as complete resolution of all CD-related symptoms). Mucosal healing was defined as absence of ulceration/erosions on ileo-colonoscopy or no inflammation on MRI if ileo-colonoscopy was not possible (eg. B2 disease). Deep remission was defined as clinical remission plus mucosal healing. Perianal response was determined by follow up MRI (reduction in enhancement, closure or fibrosis of tract compared to baseline MRI). Rates of serious adverse events (discontinuation of UST, hospitalisation or death) during follow up were described quantitatively.

3. **Results** A total of 216 patients (57.9% female; median age 39.0 years, IQR 28.8–51.8; median disease duration 9.9 years, IQR 6.0–16.5) with a median follow up of 35.0 weeks (IQR 17.4–52.0) were included. The majority of patients had ileocolonic disease (L1, 19.9%; L2, 23.1%; L3, 56.9%) and an inflammatory phenotype (B1, 43.1%; B2, 41.2%; B3, 15.7%). A total of 98.6% of patients had previously been exposed to a biologic and 55.1% had undergone previous surgery. Seventy-one percent of patients received 8-weekly maintenance dosing, whilst 25.5% and 40.7% of patients were also receiving an immunomodulator and/or steroids at initiation, respectively. At week 8, clinical response and remission rates were 45.4% and 6.0%, respectively. Twelve-month cumulative rates of clinical remission, mucosal healing (n=123) and deep remission (n=123) were 32.0%, 32.7% and 19.3%, respectively. At week 8, clinical response and remission rates were 45.4% and 6.0%, respectively. Twelve-month cumulative rates of clinical remission, mucosal healing (n=123) and deep remission (n=123) were 32.0%, 32.7% and 19.3%, respectively (figure 1). In patients with active perianal disease at initiation (n=37), 12-month cumulative rates of perianal response were 53.1%. During 140 patient years of follow up...
(PYF), 19 patients experienced a serious adverse event (13.6 per 100 PYF).

Conclusions We have shown in a large real-world cohort of complex, treatment refractory CD patients that UST is a safe and effective treatment option

**P136** IMMUNOMODULATORY MECHANISMS OF FMT IS ASSOCIATED WITH CLINICAL RESPONSE IN UC – RESULTS FROM STOP-COLITIS

1Mohammed Nabil Quraish*, 2Ye Oo, 3Andrew D Beggs, 4David Withers, 5Animesh Acharjee, 6Naveen Sharma, 7Nicholas J Loman, 8Konstantinos Gerasimidis, 9Richard Hansen, 10Georgios G koutou, 11Aila L Hart, 12Daniel R Gaya, 13Tariq I qbal. University of Birmingham Microbiome Treatment Centre, Birmingham, UK; 1Institute of Immunology and Immunotherapy, University of Birmingham, UK, UK; 2Institute of Cancer and Genomic Sciences, University of Birmingham, UK; 3Institute of Microbiology and Infection, University of Birmingham, UK; 4Human Nutrition, University of Glasgow, Glasgow, UK; 5Department of Paediatric Gastroenterology, Royal Hospital for Children Glasgow, Glasgow, UK; 6IBD Unit, St Mark’s Hospital, London, London, UK; 7Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK

10.1136/gutjnl-2020-bsgcampus.211

**Background** Studies of faecal microbiota transplantation (FMT) for treating ulcerative (UC) have shown promising results, however mechanisms by which FMT modulates inflammation remain unexplored. Through an open-label pilot of FMT in UC (STOP-Colitis) we conducted a sub-study to explore changes in host colonic mucosal immune cell subsets and gene expression following FMT.

**Methods** Patients in this study received 8 infusions of FMT over an 8 week period. Colon biopsies were obtained at baseline and at end of the study. Immunophenotyping of colonic lamina propria mononuclear cells (LPMC) and RNA sequencing was conducted on colon biopsies for differential gene expression analysis.

**Results** 17 patients were recruited to this sub-study of which 12 completed study per protocol. Response (reduction in MAYO score) was seen in 67% (8/12) of patients. Analysis of colonic LPMC populations revealed a significant increase in regulatory T cells (Tregs, CD4+CD25+CD127lowFoxP3+; Δ5.02%; p<0.01), effector Tregs (CD4+CD25+CD127-CCR7-CD45RA-; Δ12%; p<0.001), gut homing Tregs (CD4+CD25+CD127-CCR7-CD45RA-; Δ18.5%; p<0.01) and IL-10 producing CD4 cells (Δ 2.16%; p=0.04) in responders following FMT. There was a significant reduction in mucosal Th17 (CD4+CD161+CCR6+; Δ 7.69%; p=0.05) and IL-17 producing CD4 (Δ 18.1%; p=0.04) populations in FMT responders. Colonic mucosal gene expression and pathway analysis demonstrated that response to FMT was associated with significant downregulation of host antimicrobial defence response mainly REG and defensin family of anti-microbial peptides, pathogen-associated molecular pattern receptors, MHC class II antigen presentation genes and proinflammatory pathways. There was significant upregulation of butanoate and propionate metabolic pathways in FMT responders.

**Conclusion** Response to FMT is associated with a significant increase in mucosal gut homing Tregs and butanoate metabolism along with a reduction in Th17 cells and multiple anti-microbial defence and proinflammatory pathways. Exploring microbial mediators in FMT which influence immunometabolism are now under investigation to underpin novel biotherapeutic approaches.

**P137** THE IMPACT OF IBD FATIGUE ON HEALTH-RELATED QUALITY OF LIFE: A QUALITATIVE SEMI-STRUCTURED INTERVIEW STUDY

1Shellie Radford*, 2Wladyslawa Czuber-Dochan, 3Gordon W Moran, 4NIHR Nottingham Biomedical Research Centre and University Of Nottingham, Nottingham, Nottingham, UK; 5Kings College London, Florence Nightingale Faculty of Nursing, midwifery and palliative care, London, London

10.1136/gutjnl-2020-bsgcampus.212

**Background** Fatigue is a frequently reported symptom of inflammatory bowel disease (IBD), experienced by patients with active disease and in remission. Fatigue related to chronic conditions plays a significant negative role in Health-Related Quality of Life (HRQoL), but patients’ experience of this has not been described in IBD. We aimed to explore experience of IBD fatigue and its impact on HRQoL in adults diagnosed with IBD.

**Methods** Qualitative, semi-structured in-depth interviews were conducted with adults with IBD in remission, recruited from out-patient clinics in the United Kingdom. Eligibility and medical history were confirmed at recruitment. Interviews were audio-recorded and transcribed verbatim. Thematic analysis was employed to analyse the data using NVivo 12 software.

**Results** Fourteen participants (eight females, average age 37.3 years old, range 21–64) were interviewed. All identified themselves as a ‘White British’, average length of living with IBD fatigue was 10.9 years (range 9 months -17 years). Twelve participants reported that fatigue was constant and two reported intermittent fatigue. There were three key themes that reflect the patient experience: 1) The new normal’ established through attempts to adapt daily life and acceptance of IBD fatigue impact on daily life and therefore impact on HRQoL. HRQoL is negatively impacted by lack of feelings of fulfillment, not being able to continue on as before the onset of IBD fatigue and a negative perception of self in comparison to others without IBD fatigue; 2) ‘Energy as a resource’ describes participants attempts to better manage fatigue on a daily basis through planning and prioritising tasks, often prioritising employment or education above social or leisure activities; 3) ‘Keeping healthy’ encompasses participants beliefs that good nutrition, good general health and keeping active allow them to generate energy more easily allowing some situational control where they have little control over IBD symptoms and subsequently improve HRQoL. Participants reported a mix of physical activities that improved HRQoL, however none reported a specific programme of exercise.

**Conclusion** Adults with IBD fatigue try to establish a sense of ‘new normality’, through maintaining the same or similar, level of activities related to employment or education. However, this is often at the expense of personal, social and leisure activities. The study also indicates that perceptions of conserving energy through planning and prioritising tasks and high levels of social support were associated with better self-reported HRQoL. Further research is required to explore physical activity-based intervention in relation to IBD fatigue, with use of validated fatigue and HRQoL measures.